CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 135 filers reported holding CRISPR THERAPEUTICS AG in Q1 2018. The put-call ratio across all filers is 3.59 and the average weighting 1.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $768,000 | +389.2% | 12,608 | +229.4% | 0.01% | +400.0% |
Q3 2019 | $157,000 | +17.2% | 3,828 | +34.1% | 0.00% | 0.0% |
Q2 2019 | $134,000 | -32.0% | 2,855 | -48.3% | 0.00% | -50.0% |
Q1 2019 | $197,000 | +50.4% | 5,526 | +20.8% | 0.00% | +100.0% |
Q4 2018 | $131,000 | -69.3% | 4,576 | -52.5% | 0.00% | -75.0% |
Q3 2018 | $427,000 | -9.3% | 9,630 | +20.1% | 0.00% | -33.3% |
Q2 2018 | $471,000 | +756.4% | 8,021 | +571.8% | 0.01% | +500.0% |
Q1 2018 | $55,000 | +111.5% | 1,194 | +8.5% | 0.00% | – |
Q4 2017 | $26,000 | +62.5% | 1,100 | +22.2% | 0.00% | – |
Q3 2017 | $16,000 | +14.3% | 900 | 0.0% | 0.00% | – |
Q2 2017 | $14,000 | +100.0% | 900 | +200.0% | 0.00% | – |
Q1 2017 | $7,000 | – | 300 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |